Muscle loss on GLP-1s: what the 2025 evidence actually shows

The muscle-loss concern on GLP-1 receptor agonists was part of the conversation from early in the class but largely overshadowed by efficacy headlines. Through 2024–2025, better-powered studies and sub-analyses of the STEP and SURMOUNT programs put specific numbers on a question that had been mostly qualitative.

What the data says

In body-composition sub-studies of semaglutide and tirzepatide, lean mass accounts for approximately 25-40% of the total body mass lost during active treatment. This percentage is actually not dramatically different from what's observed with conventional caloric restriction in weight-loss trials — the difference is that GLP-1 drugs produce much larger total weight loss, so the absolute lean-mass loss is larger in kilograms.

Specifically: at ~15% body weight loss on semaglutide (STEP-1 range), observed lean mass loss sums to roughly 6–7% of baseline lean mass. At ~20% body weight loss on tirzepatide (SURMOUNT-1 range), lean mass loss approaches 8–10% of baseline. For a 180-pound adult with average body composition, that's roughly 10–15 pounds of lean mass, including skeletal muscle, over the course of treatment.

Why this matters more for older adults

Sarcopenia — age-related muscle loss — accelerates past age 60 and is a major contributor to disability, falls, and loss of independent function in older adults. Baseline muscle mass going into a GLP-1 course matters. A 70-year-old entering GLP-1 therapy with already-reduced muscle mass risks crossing clinical sarcopenia thresholds in ways a 40-year-old with ample baseline muscle doesn't.

Bone density concerns follow a similar pattern: caloric restriction and rapid weight loss are risk factors for bone mineral density reduction. GLP-1 trials haven't consistently shown accelerated bone loss beyond what weight-loss alone produces, but the signal warrants monitoring, particularly in postmenopausal women and older men.

What helps

Three countermeasures have empirical support for preserving lean mass during GLP-1-mediated weight loss:

**Resistance training.** Even modest resistance exercise (2–3 sessions per week of basic compound movements) reduces the percentage of weight loss that comes from lean mass. This is the highest-evidence intervention and isn't easy to dismiss.

**Adequate protein intake.** Guidelines for patients on GLP-1 typically recommend 1.2–1.6 g protein per kg body weight per day — higher than the RDA — to preserve muscle protein synthesis under caloric deficit. GI side effects can make hitting this hard; protein shakes and small frequent meals help.

**Slower dose escalation and planned plateaus.** Faster initial weight loss correlates with higher lean-mass loss percentage. Slower, more sustainable rates of weight loss produce better body-composition outcomes, even if total weight loss ends up similar.

The pharmacological frontier

Bimagrumab (a myostatin pathway antibody) paired with semaglutide is in active clinical development specifically for muscle-preserving weight loss. Early data suggests the combination can shift the composition of weight loss toward predominantly fat mass. If Phase 3 confirms, bimagrumab add-on could become a standard-of-care consideration for older adults starting GLP-1 therapy.